Pembrolizumab-combination Therapy for NSCLC- Effectiveness and Predictive Factors in Real-world Practice

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Feb 7

PMID 38322415

Authors

Magdalena Knetki-Wroblewska

Rafal Dziadziuszko

Tomasz Jankowski

Pawel Krawczyk

Maciej Bryl

Katarzyna Stencel

Anna Wrona

Artur Bandura

Jolanta Smok-Kalwat

Jolanta Rok-Knapinska

Kinga Szydziak-Zwierzynska

Krzysztof Rogoziewicz

Grzegorz Czyzewicz

Monika Wojtowicz

Marek Wojtukiewicz

Ewa Kalinka

Piotr J Wysocki

Mateusz Lobacz

Janusz Milanowski

Hubert Pawlik

Dariusz M Kowalski

Maciej Krzakowski

Affiliations

Soon will be listed here.

Abstract

Introduction: Pembrolizumab combined with chemotherapy has become the standard of care for patients with non-small-cell lung cancer (NSCLC) and the expression of programmed death ligand 1 (PD-L1) in <50% of tumour cells (TC).

Methods: We evaluated the efficacy of the treatment in real-world practice, paying attention to the predictive factors, with a special focus on low level of PD-L1 expression. This study is a multicenter retrospective analysis of patients with stage IV NSCLC.

Results: A group of 339 consecutive patients was analysed, among them 51% patients with low PD-L1 expression. In the overall population, the ORR was 40.6%, median PFS and OS were 13 months (95% CI 11.4-15) and 16.8 months (95% CI 13.3-20.3), respectively. In multivariate analysis for the entire study population, performance status - ECOG 1 vs. 0 (HR 2.2, 95%CI 1.1-4.6; p=0.02), neutrophil to lymphocyte ratio (NLR)>3 (HR 2.3, 95%CI 1.3-4.2; p=0.04), presence of liver (HR 2.0, 95%CI 1-3.7; p=0. 03) and bone metastases (HR 1.3, 95%CI 1-3; p=0.04), weight loss (HR 1.8, 95%CI 1.1-2.8; p=0.01) and sum of measurable lesions diameters >110 mm (HR 1.7, 95%CI 1-2.9, p=0.049) had a negative impact on OS.

Conclusions: In the real world, patients can clinically benefit from immunochemotherapy, regardless of the expression of PD-L1 and the histological type. Other clinicopathological factors such as performance status, extent, and location of secondary lesions have prognostic significance.

References

Novello S, Kowalski D, Luft A, Gumus M, Vicente D, Mazieres J . Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023; 41(11):1999-2006. PMC: 10082300. DOI: 10.1200/JCO.22.01990. View

Yu S, Hsiao Y, Cooper W, Choi Y, Aviles-Salas A, Chou T . The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. Pathology. 2022; 55(1):19-30. DOI: 10.1016/j.pathol.2022.07.016. View

Hong L, Negrao M, Dibaj S, Chen R, Reuben A, Bohac J . Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020; 15(9):1449-1459. DOI: 10.1016/j.jtho.2020.04.026. View

Hendriks L, Kerr K, Menis J, Mok T, Nestle U, Passaro A . Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(4):358-376. DOI: 10.1016/j.annonc.2022.12.013. View

Renaud E, Ricordel C, Corre R, Leveiller G, Gadby F, Babey H . Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). Transl Lung Cancer Res. 2023; 12(2):266-276. PMC: 9989798. DOI: 10.21037/tlcr-22-556. View

Uruga H, Mino-Kenudson M . Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. Virchows Arch. 2021; 478(1):31-44. DOI: 10.1007/s00428-021-03030-8. View

Gagne A, Wang E, Bastien N, Orain M, Desmeules P, Page S . Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations. J Thorac Oncol. 2019; 14(12):2062-2070. DOI: 10.1016/j.jtho.2019.08.2503. View

Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazieres J . A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol. 2020; 15(10):1657-1669. DOI: 10.1016/j.jtho.2020.06.015. View

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

10.

Rodriguez-Abreu D, Powell S, Hochmair M, Gadgeel S, Esteban E, Felip E . Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021; 32(7):881-895. DOI: 10.1016/j.annonc.2021.04.008. View

11.

Banna G, Cantale O, Muthuramalingam S, Cave J, Comins C, Cortellini A . Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. Int Immunopharmacol. 2022; 110:108985. DOI: 10.1016/j.intimp.2022.108985. View

12.

Aggarwal H, Bayo K, Han Y, Muehlenbein C, Zhu Y, Kim J . Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA. Immunotherapy. 2023; 15(4):267-281. DOI: 10.2217/imt-2022-0166. View

13.

Velcheti V, Hu X, Piperdi B, Burke T . Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices. Sci Rep. 2021; 11(1):9222. PMC: 8080779. DOI: 10.1038/s41598-021-88453-8. View

14.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

15.

Attili I, Valenza C, Santoro C, Antonarelli G, Trillo Aliaga P, Del Signore E . Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50. Front Oncol. 2022; 12:980765. PMC: 9399686. DOI: 10.3389/fonc.2022.980765. View

16.

Garassino M, Gadgeel S, Speranza G, Felip E, Esteban E, Domine M . Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023; 41(11):1992-1998. PMC: 10082311. DOI: 10.1200/JCO.22.01989. View

17.

Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K . Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022; 28(11):2374-2380. PMC: 9671806. DOI: 10.1038/s41591-022-01977-y. View

18.

Gadgeel S, Rodriguez-Abreu D, Halmos B, Garassino M, Kurata T, Cheng Y . Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024; 19(8):1228-1241. DOI: 10.1016/j.jtho.2024.04.011. View

19.

Waterhouse D, Lam J, Betts K, Yin L, Gao S, Yuan Y . Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 2021; 156:41-49. DOI: 10.1016/j.lungcan.2021.04.007. View

20.

Dietel M, Savelov N, Salanova R, Micke P, Bigras G, Hida T . Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study. Lung Cancer. 2019; 134:174-179. DOI: 10.1016/j.lungcan.2019.06.012. View